Predictive Historical Income Statement
POAI Stock | USD 1.64 0.05 2.96% |
Historical analysis of Predictive Oncology income statement accounts such as Other Operating Expenses of 9.6 M, Total Operating Expenses of 9.3 M, Income Tax Expense of 3.8 or Total Revenue of 899.7 K can show how well Predictive Oncology performed in making a profits. Evaluating Predictive Oncology income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Predictive Oncology's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Predictive Oncology latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Predictive Oncology is a good buy for the upcoming year.
Predictive |
About Predictive Income Statement Analysis
Predictive Oncology Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Predictive Oncology shareholders. The income statement also shows Predictive investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Predictive Oncology Income Statement Chart
Predictive Oncology Income Statement is one of the three primary financial statements used for reporting Predictive's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Predictive Oncology revenue and expense. Predictive Oncology Income Statement primarily focuses on the company's revenues and expenses during a particular period.
As of now, Predictive Oncology's Interest Expense is increasing as compared to previous years. The Predictive Oncology's current Gross Profit is estimated to increase to about 523.2 K, while Depreciation And Amortization is projected to decrease to under 702.4 K. Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Predictive Oncology. It is also known as Predictive Oncology overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Predictive Oncology's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Predictive Oncology current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Predictive Oncology. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in Predictive Stock please use our How to Invest in Predictive Oncology guide.As of now, Predictive Oncology's Interest Expense is increasing as compared to previous years. The Predictive Oncology's current Gross Profit is estimated to increase to about 523.2 K, while Depreciation And Amortization is projected to decrease to under 702.4 K.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 933.7K | 1.0M | 433.4K | 523.2K | Total Revenue | 1.4M | 1.5M | 1.8M | 899.7K |
Predictive Oncology income statement Correlations
Click cells to compare fundamentals
Predictive Oncology Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Predictive Oncology income statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Depreciation And Amortization | 8.9M | 1.0M | 6.8M | 12.0M | 739.3K | 702.4K | |
Selling General Administrative | 9.8M | 10.4M | 10.9M | 11.1M | 9.4M | 7.1M | |
Selling And Marketing Expenses | 1.9M | 584.9K | 774.5K | 1.4M | 1.5M | 913.9K | |
Other Operating Expenses | 15.2M | 13.7M | 14.9M | 16.8M | 15.7M | 9.6M | |
Operating Income | (13.8M) | (666.3K) | (13.5M) | (15.3M) | (13.9M) | (13.2M) | |
Ebit | (13.8M) | (666.3K) | (13.5M) | (15.3M) | (13.9M) | (13.2M) | |
Ebitda | (4.9M) | 358.6K | (6.7M) | (3.3M) | (13.2M) | (12.5M) | |
Total Operating Expenses | 14.7M | 13.3M | 14.4M | 16.3M | 14.4M | 9.3M | |
Net Income | (27.6M) | (37.7M) | (19.7M) | (36.2M) | (14.0M) | (14.7M) | |
Income Tax Expense | 8.2M | 11.8M | (661.7K) | 10.5M | 4.0 | 3.8 | |
Total Revenue | 1.4M | 1.3M | 1.4M | 1.5M | 1.8M | 899.7K | |
Gross Profit | 879.8K | 805.1K | 933.7K | 1.0M | 433.4K | 523.2K | |
Cost Of Revenue | 531.8K | 447.2K | 487.0K | 505.1K | 1.3M | 1.4M | |
Income Before Tax | (19.4M) | (25.9M) | (20.3M) | (25.7M) | (14.0M) | (14.7M) | |
Total Other Income Expense Net | (5.6M) | (25.2M) | (6.8M) | (10.5M) | (62.6K) | (65.8K) | |
Research Development | 3.0M | 2.4M | 315.9K | 320.3K | 188.3K | 178.9K | |
Net Income From Continuing Ops | (19.4M) | (25.9M) | (19.7M) | (25.7M) | (18.4M) | (19.3M) | |
Net Income Applicable To Common Shares | (19.7M) | (26.4M) | (19.7M) | (25.7M) | (23.2M) | (24.3M) | |
Reconciled Depreciation | 704.9K | 1.0M | 1.3M | 1.3M | 913.7K | 866.8K |
Currently Active Assets on Macroaxis
When determining whether Predictive Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Predictive Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Predictive Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Predictive Oncology Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Predictive Oncology. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in Predictive Stock please use our How to Invest in Predictive Oncology guide.Note that the Predictive Oncology information on this page should be used as a complementary analysis to other Predictive Oncology's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Predictive Stock analysis
When running Predictive Oncology's price analysis, check to measure Predictive Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Predictive Oncology is operating at the current time. Most of Predictive Oncology's value examination focuses on studying past and present price action to predict the probability of Predictive Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Predictive Oncology's price. Additionally, you may evaluate how the addition of Predictive Oncology to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
CEOs Directory Screen CEOs from public companies around the world | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |
Is Predictive Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Predictive Oncology. If investors know Predictive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Predictive Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.48) | Revenue Per Share 0.443 | Quarterly Revenue Growth (0.08) | Return On Assets (0.43) | Return On Equity (0.93) |
The market value of Predictive Oncology is measured differently than its book value, which is the value of Predictive that is recorded on the company's balance sheet. Investors also form their own opinion of Predictive Oncology's value that differs from its market value or its book value, called intrinsic value, which is Predictive Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Predictive Oncology's market value can be influenced by many factors that don't directly affect Predictive Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Predictive Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Predictive Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Predictive Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.